Get the Stockscreener App
1.94
4.30%
0.08
Pre-market:
1.46
-0.48
-24.74%
Tscan Therapeutics Inc stock is traded at $1.94, with a volume of 214.71K.
It is up +4.30% in the last 24 hours and up +6.59% over the past month.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
See More
Previous Close:
$1.86
Open:
$1.86
24h Volume:
214.71K
Relative Volume:
0.51
Market Cap:
$101.79M
Revenue:
$21.05M
Net Income/Loss:
$-89.22M
P/E Ratio:
-1.0838
EPS:
-1.79
Net Cash Flow:
$-64.50M
1W Performance:
-16.02%
1M Performance:
+6.59%
6M Performance:
+20.87%
1Y Performance:
-57.27%
1-Day Range:
$1.845
$1.97
1-Week Range:
$1.74
$2.4292
52-Week Range:
$1.02
$6.225
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Name
Tscan Therapeutics Inc
Sector
Industry
Phone
857-399-9500
Address
830 WINTER STREET, WALTHAM
Compare TCRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
1.94 | 105.55M | 21.05M | -89.22M | -64.50M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-16-24 | Initiated | BTIG Research | Buy |
| May-13-24 | Initiated | Needham | Buy |
| Jun-22-23 | Initiated | Wedbush | Outperform |
Tscan Therapeutics Inc Stock (TCRX) Latest News
TScan to focus on heme program, cuts workforce by 30% amid FDA progress - Investing.com
TScan Therapeutics Shifts Focus to Hematologic Malignancies - TipRanks
TScan Therapeutics Announces 30% Workforce Reduction, Cash Runway Extension - TradingView
TScan Therapeutics expects $2.3 million one-time charge for severance during 3 months ended Dec 31 - MarketScreener
TScan Therapeutics Expects $2.3 Million One-Time Charge For Severance During 3 Months Ended Dec 31 - TradingView
TScan Therapeutics (NASDAQ: TCRX) extends cash runway to H2 2027; cuts workforce about 30% - Stock Titan
Should you wait for a breakout in TScan Therapeutics Inc.Portfolio Risk Summary & Community Driven Trade Alerts - newser.com
Best data tools to analyze TScan Therapeutics Inc. stock2025 AllTime Highs & Reliable Trade Execution Plans - newser.com
Is TScan Therapeutics Inc. building a consolidation base2025 Year in Review & Stock Timing and Entry Methods - newser.com
Technical signs of recovery in TScan Therapeutics Inc.2025 Top Decliners & Daily Entry Point Alerts - newser.com
Reversal indicators forming on TScan Therapeutics Inc. stockProfit Target & Daily Oversold Stock Bounce Ideas - newser.com
Trend analysis for TScan Therapeutics Inc. this weekEarnings Overview Summary & Short-Term Swing Trade Alerts - newser.com
Applying chart zones and confluence areas to TScan Therapeutics Inc.Trade Exit Report & Consistent Profit Trading Strategies - newser.com
What technical models suggest about TScan Therapeutics Inc.’s comebackMarket Volume Report & Detailed Earnings Play Strategies - newser.com
Is TScan Therapeutics Inc. still worth holding after the dipBull Run & Technical Pattern Recognition Alerts - newser.com
How TScan Therapeutics Inc. stock reacts to global recession fearsQuarterly Profit Report & AI Based Buy and Sell Signals - newser.com
Can swing trading help recover from TScan Therapeutics Inc. lossesJuly 2025 Drop Watch & Accurate Buy Signal Alerts - newser.com
Is TScan Therapeutics Inc. stock positioned well for digital economy2025 Stock Rankings & Low Drawdown Momentum Ideas - newser.com
How TScan Therapeutics Inc. stock performs in high volatility marketsJuly 2025 Decliners & Low Drawdown Investment Strategies - newser.com
Can TScan Therapeutics Inc. stock maintain growth trajectoryEarnings Beat & Stock Portfolio Risk Control - newser.com
Applying sector rotation models to TScan Therapeutics Inc.Share Buyback & Verified Trade Idea Suggestions - newser.com
Using data filters to optimize entry into TScan Therapeutics Inc.2025 Pullback Review & Reliable Breakout Forecasts - newser.com
Tscan Therapeutics Inc Stock (TCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):